United Therapeutics Corporation $UTHR Holdings Decreased by QRG Capital Management Inc.

QRG Capital Management Inc. decreased its holdings in United Therapeutics Corporation (NASDAQ:UTHR) by 76.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,099 shares of the biotechnology company’s stock after selling 13,671 shares during the period. QRG Capital Management Inc.’s holdings in United Therapeutics were worth $1,718,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. F m Investments LLC grew its holdings in shares of United Therapeutics by 1.3% during the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company’s stock valued at $741,000 after acquiring an additional 33 shares in the last quarter. HB Wealth Management LLC boosted its position in United Therapeutics by 2.9% during the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 35 shares during the last quarter. WealthCollab LLC grew its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Park Avenue Securities LLC increased its position in United Therapeutics by 1.7% in the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company’s stock worth $676,000 after purchasing an additional 39 shares during the last quarter. Finally, Coldstream Capital Management Inc. raised its stake in shares of United Therapeutics by 2.0% during the 2nd quarter. Coldstream Capital Management Inc. now owns 2,145 shares of the biotechnology company’s stock worth $616,000 after purchasing an additional 43 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

UTHR has been the topic of several recent research reports. UBS Group raised their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. HC Wainwright increased their price target on shares of United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a report on Wednesday, October 29th. Finally, Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $509.50.

United Therapeutics Stock Down 1.5%

Shares of NASDAQ:UTHR opened at $464.93 on Tuesday. The company has a market cap of $20.02 billion, a price-to-earnings ratio of 17.62, a PEG ratio of 2.42 and a beta of 0.84. The business has a 50 day moving average price of $487.07 and a 200 day moving average price of $410.84. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analyst estimates of $812.87 million. United Therapeutics had a return on equity of 18.83% and a net margin of 40.65%.The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the company earned $6.39 earnings per share. Analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Buying and Selling

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In the last ninety days, insiders have sold 571,314 shares of company stock worth $269,609,063. 10.30% of the stock is owned by corporate insiders.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.